Hot Topics

In plain language: CAR-T therapy, which already works for certain blood cancers, is being repurposed to essentially "reboot" the immune system. Doctors remove some of your T-cells, engineer them in a lab to target and destroy the misfiring B-cells causing your autoimmune disease, then infuse them back.

Why it matters: Most current treatments suppress the whole immune system indefinitely. This approach targets the problem cells specifically — and the early results show remission can last without ongoing medication.

Caveat: Still in early trials. Not widely available yet, and the process is complex and expensive. But it represents a genuine paradigm shift from "managing symptoms forever" toward "potential cure."

In plain language: GLP-1 drugs weren't designed for IBD — they were designed for diabetes and weight management. But it turns out they suppress NF-κB, a master switch for inflammation, and appear to strengthen the gut's mucosal lining.

Why it matters: These are drugs already approved and widely prescribed. If the IBD benefits hold up in clinical trials, patients might access this benefit relatively quickly compared to brand-new drug development.

Caveat: These are real-world database studies, not randomized controlled trials. Confounding factors exist. Mount Sinai's 2026 gastroenterology report calls for formal IBD-specific trials. Don't ask your doctor for Ozempic as an IBD treatment based on this alone — but it's a promising signal.

In plain language: Current biologics each block one inflammatory pathway. Some patients don't respond because IBD involves multiple pathways simultaneously. Dual therapy stacks two blockers — like combining an IL-23 inhibitor with a JAK inhibitor — to shut down more of the fire at once.

IL-23 inhibitors leading the charge: Skyrizi (risankizumab, AbbVie), Omvoh (mirikizumab, Lilly), and guselkumab (J&J) are all being studied in combination regimens. Omvoh now has the longest efficacy data — 4 years in UC and 3 years in Crohn's.

For patients: If you've failed multiple biologics, dual therapy trials may be an option to ask your GI about. ClinicalTrials.gov lists active enrollment opportunities.

In plain language: Obinutuzumab is a CD20-targeting antibody that depletes B-cells (the immune cells that attack your own tissue in lupus). It was already approved for certain blood cancers — this would be its first lupus indication.

The numbers: 76.7% SRI-4 response (a composite lupus disease activity score) vs 53.5% with placebo. That's a meaningful gap and why the FDA fast-tracked review.

Timeline: If approved in December 2026, it would become one of only three drugs FDA-approved specifically for SLE (alongside belimumab and anifrolumab), giving lupus patients another treatment option where choices have historically been limited.

In plain language: Anifrolumab blocks type I interferons — proteins that are overactive in lupus and drive inflammation. It's been available since 2021 but required sitting in an infusion center every month. The autoinjector changes that.

Why this matters practically: For college students with lupus, monthly IV infusions mean missing class, arranging rides, and spending hours at a clinic. A weekly home injection dramatically improves quality of life and treatment adherence.

Ask your rheum: If you're currently on IV Saphnelo, ask your rheumatologist whether you're a candidate to switch to the autoinjector formulation.

In plain language: Vedolizumab (Entyvio) targets a gut-specific integrin, meaning it blocks inflammation specifically in the GI tract rather than suppressing the whole immune system. It's been used in adults for years — now there's trial evidence it works safely in young children too.

Why it matters: Pediatric IBD patients historically had very limited biologic options. This trial enrolled 120 children at sites worldwide, and the data may support an expanded FDA indication for vedolizumab in pediatric UC.

In plain language: Instead of the complex viral engineering used in cancer CAR-T, this approach uses mRNA — the same platform as COVID vaccines — to temporarily reprogram T-cells. It's cheaper, faster to manufacture, and potentially safer.

Broader significance: If the mRNA delivery platform works for myasthenia gravis, it could be adapted for other autoimmune conditions that share the B-cell-driven pathology, including lupus, RA, and inflammatory myopathies.

In plain language: HLA-DR4 and related variants in the HLA gene region are the strongest known genetic risk factors for RA. Instead of treating the downstream inflammation, RheumaGen's approach edits those genes to remove the root cause — more like fixing the code than patching the symptoms.

Long-term potential: If successful, this could eventually mean a one-time treatment that prevents or permanently reverses RA rather than managing it lifelong. Phase 1 trials are focused on safety — this is still years away from standard care, but the concept is genuinely novel.

In plain language: Regular probiotics (Lactobacillus, etc.) colonize the gut but can't do much therapeutically. CRISPR-engineered next-gen probiotics are programmed to detect when inflammation spikes and release specific molecules — butyrate, anti-TNF peptides, or other therapeutics — only when needed.

Stars of this space: Akkermansia muciniphila strengthens the gut mucosal barrier. Faecalibacterium prausnitzii produces butyrate and has strong anti-inflammatory effects. Both are drastically depleted in IBD and autoimmune patients.

Still preclinical: Most engineered probiotic studies are in animal models or very early human trials. But the AGA highlighted this as one of the most exciting emerging directions for IBD care in 2026.

In plain language: BTK (Bruton's tyrosine kinase) is a signaling protein critical for B-cell activation. Blocking it dampens the autoimmune response. Previous BTK inhibitors were used for blood cancers — rilzabrutinib is being developed specifically for autoimmune diseases.

Bigger picture: BTK inhibitors are being studied across multiple autoimmune conditions including ITP, lupus, Sjögren's syndrome, and RA. An oral drug with this mechanism could eventually replace or augment current biologics for several conditions — and pills are far more convenient than infusions.